文献速递慢性肾脏病肾小球疾病

CONFIDENCE试验基线特征:非奈利酮与恩格列净联合治疗CKD合并2型糖尿病

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

CONFIDENCE是一项正在进行的随机双盲2期试验,纳入818例CKD合并2型糖尿病患者,eGFR 30-90 mL/min/1.73 m2且UACR≥100至<5000 mg/g,随机接受非奈利酮联合恩格列净、非奈利酮单药或恩格列净单药治疗,主要终点为第180天UACR相对变化。本文报告基线特征:平均eGFR 54.2 mL/min/1.73 m2,中位UACR 583 mg/g。

要点

  • 纳入CKD合并T2D患者,eGFR 30-90、UACR 100-5000 mg/g,已用最大耐受剂量RAS抑制剂。
  • 三组分别接受非奈利酮+恩格列净、非奈利酮+安慰剂、恩格列净+安慰剂。
  • 主要终点为第180天UACR相对基线变化,旨在验证联合优于单药。

核心结论

  • CONFIDENCE试验入组了多样化的CKD合并T2D人群,将明确同时起始非奈利酮与SGLT2i联合治疗对比单药对延缓CKD进展的影响。

研究设计与样本

  • CONFIDENCE为正在进行的、已完全入组的随机、对照、双盲、多中心2期临床试验。
  • 2022年7月至2024年8月期间,从14个国家143个中心随机纳入818例成人CKD合并T2D患者。

主要发现

  • 平均(标准差)eGFR为54.2(17.1)mL/min/1.73 m2,中位(四分位距)UACR为583(292, 1140)mg/g。
  • 平均(标准差)HbA1c为7.3(1.2)%,平均收缩压/舒张压为135.2/77.3 mmHg。
  • 使用GLP-1受体激动剂和胰岛素者分别为182例(23%)和313例(39%)。
  • 合并动脉粥样硬化性心血管疾病、糖尿病视网膜病变和心力衰竭病史者分别为223例(28%)、126例(16%)和30例(4%)。

关键数值与推荐

  • 入组标准:年龄≥18岁,CKD合并T2D,eGFR 30-90 mL/min/1.73 m2,UACR≥100至<5000 mg/g。
  • 筛选时已使用最大临床耐受剂量RAS抑制剂超过1个月。
  • 随机按1:1:1分配,恩格列净10 mg每日一次,非奈利酮10或20 mg每日一次(依据基线eGFR)。
  • 随机分层因素为eGFR(<60或≥60 mL/min/1.73 m2)和UACR(≤850或>850 mg/g)。

临床怎么用

  • 该试验针对已使用最大耐受剂量RAS抑制剂的CKD合并T2D患者,探索非奈利酮与恩格列净早期联合治疗的获益。
  • 基线特征显示入组人群涵盖不同eGFR和UACR水平,并合并多种心血管代谢疾病。

局限性

  • 本文仅报告基线特征,尚未报告主要终点结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitors (SGLT2is) both reduce chronic kidney disease (CKD) progression and improve kidney/cardiovascular (CV) outcomes. The CONFIDENCE (COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint) study (NCT05254002; EudraCT 2021-003037-11) hypothesis is that early combination of finerenone and empagliflozin, an SGLT2i, is superior to either drug alone in reducing urine albumin-to-creatinine ratio (UACR) over 6 months. METHODS: CONFIDENCE is an ongoing, fully enrolled, randomized, controlled, double-blind, multicentre phase 2 clinical trial in adults (≥18 years of age) with CKD and type 2 diabetes (T2D), estimated glomerular filtration rate (eGFR) of 30-90 mL/min/1.73 m2 and UACR of ≥100 to <5000 mg/g. Participants taking the clinically maximum tolerated dose of a renin-angiotensin system inhibitor for >1 month at screening were eligible. Participants were randomized 1:1:1 to once-daily finerenone plus empagliflozin, finerenone plus placebo, or empagliflozin plus placebo; doses were 10 mg once daily for empagliflozin and 10 or 20 mg once daily for finerenone, depending on eGFR at baseline. Randomization was stratified by eGFR (<60 or ≥60 mL/min/1.73 m2) and UACR (≤850 or >850 mg/g). The primary efficacy outcome is the relative change in UACR from baseline at Day 180. RESULTS: There were 818 participants randomized across 143 sites from 14 countries between July 2022 and August 2024. Mean (standard deviation) eGFR was 54.2 (17.1) mL/min/1.73 m2. Median (interquartile range) UACR was 583 (292, 1140) mg/g. Mean (standard deviation) HbA1c was 7.3 (1.2)%. Mean systolic/diastolic blood pressure was 135.2/77.3 mmHg. Glucagon-like peptide-1 receptor agonists and insulin were used by 182 (23%) and 313 (39%) participants, respectively. Atherosclerotic CV disease, diabetic retinopathy and a history of heart failure were present in 223 (28%), 126 (16%) and 30 (4%) participants, respectively. CONCLUSIONS: The CONFIDENCE trial enrolled a diverse population with CKD and T2D, and will determine the impact of simultaneous initiation of combination finerenone and an SGLT2i versus individual therapy on potentially mitigating the progression of CKD in people with T2D. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT05254002; EudraCT 2021-003037-11.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Green JB, Heerspink HJL, et al. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025. PMID: 39916475. doi:10.1093/ndt/gfaf022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。